

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Suzhou Basecare Medical Corporation Limited
蘇州貝康醫療股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2170)

PROFIT ALERT

This announcement is made by Suzhou Basecare Medical Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors the following updates on the Group’s financials which are based on a preliminary review of the unaudited consolidated management accounts of the Group for the six months ended June 30, 2023 and the latest information currently available to the Board:

1. The total revenue of the Group for the six months ended June 30, 2023 is expected to be within the range of RMB79.4 million to RMB87.8 million, representing an increase in the range of 15.7% to 28.0% from RMB68.6 million for the six months ended June 30, 2022. The increase in revenue of the Group is mainly attributable to the sales of PGT-A kits and cryopreservation system.
2. The gross profit of the Group for the six months ended June 30, 2023 is expected to be within the range of RMB30.2 million to RMB36.4 million, representing an increase in the range of no higher than 20.5% from RMB30.2 million for the six months ended June 30, 2022. The increase in gross profit is mainly due to increased revenue. The Group’s overall gross profit margin for the six months ended June 30, 2023 is expected to be within the range of 39.0% to 41.5%, which remains stable compared to the same corresponding period of 2022.

As disclosed in the Company's announcement dated June 21, 2023, the acquisition of BMX Holdco Pte. Ltd. ("**BMX Holdco**") by the Company was completed on June 21, 2023 and BMX Holdco has become a wholly owned subsidiary of the Company since then. Given the strategic significance of BMX Holdco to the Group, and with a view to providing more information about BMX Holdco to the Shareholders and potential investors, the Company also sets forth below the latest financial results of BMX Holdco, which is based on a preliminary review of the unaudited consolidated management accounts of BMX Holdco for the six months ended June 30, 2023:

1. The total revenue of BMX Holdco for the six months ended June 30, 2023 is expected to be within the range of RMB43.6 million to RMB44.6 million, representing an increase in the range of 19.7% to 22.5% from RMB36.4 million for the six months ended June 30, 2022. The increase in revenue of BMX Holdco is mainly attributable to the increase in sales in certain Asian countries.
2. The gross profit of BMX Holdco for the six months ended June 30, 2023 is expected to be within the range of RMB24.9 million to RMB25.9 million, representing an increase in the range of 10.6% to 15.1% from RMB22.5 million for the six months ended June 30, 2022. The increase in gross profit is due to increased revenue.

The Company is still in the process of finalizing the financial results of the Group for the six months ended June 30, 2023. The relevant financial information disclosed above is unaudited and based on the preliminary internal information of the Group, which may be subject to change and may differ from the figures to be disclosed in the audited or unaudited consolidated financial statements to be published by the Company on an annual or half-yearly basis due to various uncertainties during the process of collating such information. Such information has not been audited or reviewed by the auditors of the Company or the audit committee of the Board of the Company. They shall not be taken as a measure or indication of the Group's current or future operating or financial performance, nor shall they be taken as a representation by the Group of the corresponding figures as may be provided in due course in the Group's audited or unaudited consolidated financial statements. As such, the above information is provided for Shareholders and potential investors' reference only. Shareholders and potential investors are advised to read carefully about the interim results announcement of the Company for the six months ended June 30, 2023, which is expected to be published in August 2023 in accordance with the requirements of the Listing Rules.

Shareholders and potential investors are advised not to place any reliance on the information disclosed herein but to exercise due caution when dealing in the securities of the Company. When in doubt, Shareholders and potential investors are advised to seek professional advice from professional or financial advisers.

By order of the Board
Suzhou Basecare Medical Corporation Limited
Dr. Liang Bo
Chairman and General Manager

Suzhou, PRC, July 18, 2023

As of the date of this announcement, the Board comprises Dr. LIANG Bo, Mr. KONG Lingyin and Ms. YANG Ying as executive Directors; Mr. XU Wenbo and Mr. WANG Weipeng as non-executive Directors; and Dr. KANG Xixiong, Dr. HUANG Taosheng and Mr. LAM Siu Wing as independent non-executive Directors.